Cormorant Asset Management’s Cytokinetics CYTK Stock Holding History

Cormorant Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-296,000	Closed	-$10.4M	–	67
2023 Q1	$10.4M	Hold	296,000	–	–	0.69%	37
2022 Q4	$13.6M	Hold	296,000	–	–	0.91%	34
2022 Q3	$14.3M	Sell	296,000 -104,000	-26%	-$5.01M	1%	35
2022 Q2	$15.7M	Hold	400,000	–	–	1.19%	27
2022 Q1	$14.7M	Sell	400,000 -300,000	-43%	-$10.7M	1.13%	26
2021 Q4	$31.9M	Sell	700,000 -300,000	-30%	-$11.6M	1.9%	15
2021 Q3	$35.7M	Buy	+1,000,000	New	+$29.4M	1.45%	19

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Cormorant Asset Management's CYTK Position: Q2 2023 in Review

Cormorant Asset Management sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 296,000 shares — an estimated $10.4M sold.

Cormorant Asset Management first reported a position in CYTK in Q3 2021 and held it in 7 quarters. The position peaked at $35.7M in Q3 2021. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

Cormorant Asset Management reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
Cormorant Asset Management sold 296,000 Cytokinetics shares in Q2 2023, an estimated $10.4M.
Cormorant Asset Management first reported a position in Cytokinetics in Q3 2021 and held it in 7 quarters.
Cormorant Asset Management's Cytokinetics position peaked at $35.7M in Q3 2021.
253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.